Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1999, p. 2299-2301, Vol. 43, No. 9
Department of Microbiology, Mount Sinai and
Princess Margaret Hospitals, and Department of Pathobiology and
Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada
Received 5 January 1999/Returned for modification 3 March
1999/Accepted 6 July 1999
Among 418 blood culture isolates of viridans group streptococci
obtained between 1995 and 1997, the in vitro rates of nonsusceptibility to penicillin, erythromycin, tetracycline, and
trimethoprim-sulfamethoxazole were 28, 29, 24, and 14%, respectively.
The most prevalent group (125 strains) was Streptococcus
mitis, followed by Streptococcus sanguis (56 strains). For 236 (56%) strains resistant to one or more antibiotics,
the ciprofloxacin MIC at which 90% of the isolates were inhibited
(MIC90) was 4 µg/ml, whereas the MIC90s of
trovafloxacin, grepafloxacin, and gatifloxacin were 0.25 µg/ml.
Viridans group streptococci,
although part of the normal human flora, are a common cause of sepsis
in neutropenic patients (3) and bacterial endocarditis
(17). Recently, there have been several reports describing
emerging antimicrobial resistance in this group of streptococci
(1, 2, 7, 15). In 1996, 56% of strains in the United States
were nonsusceptible to penicillin (7), an antimicrobial that
had exhibited good activity against these organisms 20 years ago
(4).
This study examined the activities of several antimicrobial agents,
comprising those commonly used for treating infections caused by
viridans group streptococci and those that could be potentially useful,
such as the fluoroquinolones, with enhanced activity against
gram-positive organisms (14).
Between May 1995 and March 1997, 418 blood culture isolates of viridans
group streptococci were collected through the Canadian Bacterial
Surveillance Network, a system of 55 private laboratories and
community- and university-affiliated hospitals representing nine
provinces across Canada, of which 39 provided 3 or more isolates. Isolates were sent to Mount Sinai Hospital for susceptibility testing
and species identification. The latter was carried out with a
combination of standard biochemical tests (18), the Vitek GPI system (bioMerieux Vitek Inc., Hazelwood, Mo.), and the API 20 Strep system (bioMerieux sa, Marcy l'Etoile, France) according to the
manufacturer's instructions. Susceptibility testing was performed by
broth microdilution, in accordance with National Committee for Clinical
Laboratory Standards (NCCLS) guidelines (13). Panels were
prepared in-house, by using cation-adjusted Mueller-Hinton broth (Difco
Laboratories, Detroit, Mich.) supplemented with 5% lysed horse blood.
The in vitro activities of the following agents were tested:
penicillin, cefuroxime, ceftriaxone, cefotaxime, erythromycin,
clindamycin, vancomycin, tetracycline, trimethoprim-sulfamethoxazole (TM/S [19:1]), ciprofloxacin (Sigma-Aldrich Canada, Oakville, Ontario), sparfloxacin (Rhone-Poulenc Rorer, Collegeville, Pa.), levofloxacin (Ortho-McNeil Pharmaceuticals, Spring House, Pa.), and
gatifloxacin (Bristol-Myers Squibb Company, Princeton, N.J.). Streptococcus pneumoniae ATCC 49619 was used as a control.
MICs of drugs were read after 20 to 24 h of incubation in ambient
air at 35°C.
Relatively high rates of resistance against several antimicrobials were
noted (Table 1). Among the 418 isolates,
116 (28%) were nonsusceptible to penicillin, with MICs ranging from
0.12 to 32 µg/ml (MIC at which 90% of the isolates are inhibited
[MIC90], 1 µg/ml). Of these, 91 strains (22%)
demonstrated intermediate resistance (MIC, 0.25 to 2 µg/ml), and 25 (6%) showed high resistance (MIC,
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro Activities of Fluoroquinolones against
Antibiotic-Resistant Blood Culture Isolates of Viridans Group
Streptococci from across Canada
and
ABSTRACT
Top
Abstract
Text
Appendix
References
TEXT
Top
Abstract
Text
Appendix
References
4 µg/ml). Among the strains
showing high resistance, the penicillin MICs were 4 µg/ml for 16 strains, 8 µg/ml for 9 strains, and 32 µg/ml for 1 strain. The rate
of penicillin nonsusceptibility found in this study is lower than the
rates of 56% reported in the United States (7) and 37% in
New Zealand (15). In a study in Spain of 410 viridans
strains isolated from blood, 34% were found to be nonsusceptible to
penicillin (5). Predictably, nonsusceptibilities to both
amoxicillin and ceftriaxone were also relatively high at 12%, and the
MIC90s of these two agents were the same as that for
penicillin at 1 µg/ml.
TABLE 1.
In vitro susceptibility of 418 blood culture viridans
group streptococci to selected antimicrobial agents
Interestingly, although 29% of the strains were nonsusceptible to erythromycin, only 4% were nonsusceptible to clindamycin, and these did not show inducible resistance. This suggests that resistance was not due to the presence of an erm methylase, which confers resistance to macrolides, lincosamides, and streptogramin B type antimicrobials (22), but is more likely due to the high prevalence of an efflux mechanism, such as is conferred by the mef gene, which selectively confers resistance to erythromycin but not to clindamycin (20). High rates of resistance to erythromycin in blood culture isolates have been observed previously in Spain (39%) (1) and the United States (38%) (7); however, susceptibility to clindamycin was not examined. Other antibiotics to which strains showed a high level of nonsusceptibility were tetracycline at 24% and TM/S at 14%.
Emergence of high rates of resistance to various antimicrobials was surprising, considering that 173 (60%) strains were from community-based hospitals (<200 beds) rather than tertiary care hospitals. There was no significant difference (P = 0.8) in levels of penicillin resistance between strains from the two groups of hospitals, and patterns of resistance to the other antibiotics were also similar.
In S. pneumoniae, it has been noted that penicillin-resistant strains tend to be resistant to other unrelated antimicrobials, and resistance is generally low in penicillin-susceptible strains (19). However, this did not appear to be the case in this group of viridans streptococci, and rates of resistance to certain antibiotics were relatively high among penicillin-susceptible strains. Of 302 penicillin-susceptible isolates, 60 (20%) showed nonsusceptibility to erythromycin, 68 (23%) were nonsusceptible to tetracycline, and 15 (5%) were nonsusceptible to TM/S. In the case of tetracycline, the resistance rates were almost identical in penicillin-susceptible and nonsusceptible strains at 23 and 25%, respectively, which is different from the pattern found in S. pneumoniae strains.
Of the 418 strains tested, 236 showed resistance to one or more of the
antimicrobial agents listed in Table 1. These strains were tested
against a panel of fluoroquinolones as shown in Table 2. The ciprofloxacin MIC50
and MIC90 were 4 and 2 µg/ml, respectively, and the
ofloxacin MIC90 and MIC50 were both 2 µg/ml.
By comparison, with the exception of levofloxacin (with a
MIC90 of 1 µg/ml), the MICs of the other fluoroquinolones
were 0.5 or less. The MICs of trovafloxacin, grepafloxacin, and
gatifloxacin were at least fourfold lower than those of ciprofloxacin,
ofloxacin, and levofloxacin. Two strains showed reduced susceptibility
to all of the fluoroquinolones tested, with MICs of ciprofloxacin and
ofloxacin of 32 µg/ml and MICs of sparfloxacin, gatifloxacin, and
grepafloxacin of 4 to 8 µg/ml.
|
Identification at the group level was carried out with the 236 strains
showing resistance to one or more antibacterial agents. Antimicrobial
activity against 211 strains belonging to the most prevalent groups is
shown in Table 3. Groups which
encompassed fewer than 10 strains were not included:
Streptococcus milleri (7 strains), Streptococcus
bovis (6 strains), and Streptococcus mutans (3 strains). In addition, small numbers of strains (e.g., three or four)
which did not fall into easily identifiable groups, such as
Streptococcus acidominus, were also excluded. The largest number of isolates (59%) belonged to the Streptococcus
mitis group. Of 125 S. mitis isolates, 50 (40%) were
nonsusceptible to penicillin and 66 (53%) were nonsusceptible to
erythromycin. The two strains which showed reduced susceptibility to
all of the fluoroquinolones (Table 2) belonged to the S. mitis group. In the Streptococcus sanguis group,
comprising 56 strains, 55% were nonsusceptible to penicillin.
|
The results of this study show that 28% of bloodstream isolates of viridans group streptococci are nonsusceptible to penicillin, with as many as 40% of S. mitis strains, the most prevalent group, showing nonsusceptibility. The MIC of penicillin for one S. milleri strain (Streptococcus intermedius) was 32 µg/ml. This is of concern, since S. pneumoniae can acquire resistance, as represented by a MIC of penicillin as high as 64 µg/ml, by horizontal transfer from S. mitis in vitro (8, 12). The current rate of penicillin resistance (intermediate plus high) in pneumococci in Canada is 14% (6, 19), which is considerably less than that found in this study for viridans group streptococci.
Our data indicate that the newer fluoroquinolones exhibit good in vitro
activity against viridans group streptococci, including isolates known
to have intermediate or high resistance to penicillin and other
-lactam antibiotics. Currently, there are no interpretative standards with respect to the efficacy of most fluoroquinolones against
streptococci. However, trovafloxacin, grepafloxacin, and gatifloxacin
showed excellent activity in vitro, with MIC90s of 0.25 µg/ml, a 4- to 16-fold decrease compared to levofloxacin, ofloxacin,
and ciprofloxacin. Trovafloxacin has been shown to decrease bacterial
counts of an S. mitis strain and an S. sanguis strain showing reduced susceptibility to ciprofloxacin in an animal model of streptococcal endocarditis (9). Our work confirms the results of other studies showing that newer fluoroquinolones have
better activity against clinical isolates of viridans streptococci (9, 11). However, mutations in the topoisomerase genes
parC and gyrA have been shown to occur both in
vitro and in vivo in response to fluoroquinolone exposure and treatment
(21). Blood culture isolates of viridans group streptococci
with reduced susceptibility to ciprofloxacin (MIC90, 8 to
16 µg/ml) have already been described (9-11, 16), and
resistance to newer fluoroquinolones will likely develop. Consequently,
ongoing surveillance for the development of fluoroquinolone resistance
in viridans streptococci is essential.
| |
APPENDIX |
|---|
|
Top
Abstract
Text
Appendix
References
|
|---|
Investigators of the Canadian Bacterial Surveillance Network include Andrew Simor, Daryl J. Hoban, George G. Zhanel, Kevin Forward, Lewis Abbott, Joseph Blondeau, Gilles Murray, Gurmeet Randhawa, Godfrey Harding, Donna Hinds, Christiane Gaudreau, R. Roy, David Groves, Michel G. Bergeron, Dan Gregson, Peter Jessamine, Pamela Kibsey, Robert Rennie, Pierre L. Turgeon, P. Leighton, Louise Thibault, M. Laverdiere, Magdalena Kuhn, Roland Lewis, Karl Weiss, Phillipe Jutras, Lionell Mandell, D. Church, E. Blondeau, J. Galbriath, and J. Hutchinson.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant from the Canadian Bacterial Diseases Network and the Bristol-Myers Squibb Company, Princeton, N.J.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, 600 University Ave., Rm. 1483, Toronto, Ontario, Canada M5G 1X5. Phone: (416) 586-8549. Fax: (416) 586-8746. E-mail: jdeazavedo{at}mtsinai.on.ca.
Members are listed in the Appendix.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
Appendix
References
|
|---|
| 1. | Alcaide, F., J. Carratala, J. Liñares, F. Gudiol, and R. Martin. 1996. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob. Agents Chemother. 40:2117-2120[Abstract]. |
| 2. |
Alcaide, F.,
J. Liñares,
R. Pallares,
J. Carratala,
M. A. Benitez,
F. Gudiol, and R. Martin.
1995.
In vitro activities of 22 -lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood.
Antimicrob. Agents Chemother.
39:2243-2247[Abstract].
|
| 3. | Bochud, P. Y., T. Calandra, and P. Francioli. 1994. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am. J. Med. 97:256-264[Medline]. |
| 4. | Bourgault, A. M., W. R. Wilson, and J. A. Washington. 1979. Antimicrobial susceptibilities of species of viridans streptococci. J. Infect. Dis. 140:316-321[Medline]. |
| 5. | Carratala, J., F. Alcaide, A. Fernandez-Sevilla, X. Corbella, J. Linares, and F. Gudiol. 1995. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin. Infect. Dis. 20:1169-1173[Medline]. |
| 6. |
Chen, D. K.,
A. McGeer,
J. C. De Azavedo, and D. E. Low.
1999.
Decreased susceptibility of Streptococcus pneumoniae from across Canada to fluoroquinolones.
N. Engl. J. Med.
341:233-239 |
| 7. | Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894[Abstract]. |
| 8. | Dowson, C. G., T. J. Coffey, C. Kell, and R. A. Whiley. 1993. Evolution of penicillin resistance in Streptococcus pneumoniae: the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae. Mol. Microbiol. 9:635-643[Medline]. |
| 9. |
Entenza, J. M.,
J. Vouillamoz,
M. P. Glauser, and P. Moreillon.
1999.
Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
Antimicrob. Agents Chemother.
43:77-84 |
| 10. |
González, I.,
M. Georgiou,
F. Alcaide,
D. Balas,
J. Liñares, and A. G. de la Campa.
1998.
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
Antimicrob. Agents Chemother.
42:2792-2798 |
| 11. | Kerr, K. G., H. T. Armitage, and P. H. McWhinney. 1999. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. Support Care Cancer 7:28-30[Medline]. |
| 12. | Konig, A., R. R. Reinert, and R. Hakenbeck. 1998. Streptococcus mitis with unusually high level resistance to beta-lactam antibiotics. Microb. Drug Resist. 4:45-49. [Medline] |
| 13. | National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial susceptibility testing. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. |
| 14. |
Piddock, L. J.,
M. Johnson,
V. Ricci, and S. L. Hill.
1998.
Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
Antimicrob. Agents Chemother.
42:2956-2960 |
| 15. | Pottumarthy, S., and A. J. Morris. 1998. Detection of decreased penicillin susceptibility in viridans group streptococci. Pathology 30:188-191[Medline]. |
| 16. |
Poutanen, S. M.,
J. De Azavedo,
B. M. Willey,
D. E. Low, and K. S. MacDonald.
1999.
Molecular characterization of multidrug resistance in Streptococcus mitis.
Antimicrob. Agents Chemother.
43:1505-1507 |
| 17. | Roberts, R. B., A. G. Krieger, N. L. Schiller, and K. C. Gross. 1979. Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. Rev. Infect. Dis. 1:955-966[Medline]. |
| 18. | Ruoff, K. L. 1995. Streptococcus, p. 299-307. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C. |
| 19. | Simor, A. E., M. Louie, the Canadian Bacterial Surveillance Network, and D. E. Low. 1996. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2190-2193[Abstract]. |
| 20. | Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824[Abstract]. |
| 21. | Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510[Abstract]. |
| 22. | Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585[Medline]. |
Antimicrobial Agents and Chemotherapy, September 1999, p. 2299-2301, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Balsalobre, L., de la Campa, A. G.
(2008). Fitness of Streptococcus pneumoniae Fluoroquinolone-Resistant Strains with Topoisomerase IV Recombinant Genes. Antimicrob. Agents Chemother.
52: 822-830
[Abstract] [Full Text] -
Rodriguez-Avial, I., Rodriguez-Avial, C., Culebras, E., Picazo, J. J.
(2005). In Vitro Activity of Telithromycin against Viridans Group Streptococci and Streptococcus bovis Isolated from Blood: Antimicrobial Susceptibility Patterns in Different Groups of Species. Antimicrob. Agents Chemother.
49: 820-823
[Abstract] [Full Text] -
Prabhu, R. M., Piper, K. E., Baddour, L. M., Steckelberg, J. M., Wilson, W. R., Patel, R.
(2004). Antimicrobial Susceptibility Patterns among Viridans Group Streptococcal Isolates from Infective Endocarditis Patients from 1971 to 1986 and 1994 to 2002. Antimicrob. Agents Chemother.
48: 4463-4465
[Abstract] [Full Text] -
Cerda Zolezzi, P., Laplana, L. M., Calvo, C. R., Cepero, P. G., Erazo, M. C., Gomez-Lus, R.
(2004). Molecular Basis of Resistance to Macrolides and Other Antibiotics in Commensal Viridans Group Streptococci and Gemella spp. and Transfer of Resistance Genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother.
48: 3462-3467
[Abstract] [Full Text] -
Grohs, P., Houssaye, S., Aubert, A., Gutmann, L., Varon, E.
(2003). In Vitro Activities of Garenoxacin (BMS-284756) against Streptococcus pneumoniae, Viridans Group Streptococci, and Enterococcus faecalis Compared to Those of Six Other Quinolones. Antimicrob. Agents Chemother.
47: 3542-3547
[Abstract] [Full Text] -
Seppala, H., Haanpera, M., Al-Juhaish, M., Jarvinen, H., Jalava, J., Huovinen, P.
(2003). Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother
52: 636-644
[Abstract] [Full Text] -
Balsalobre, L., Ferrandiz, M. J., Linares, J., Tubau, F., de la Campa, A. G.
(2003). Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother.
47: 2072-2081
[Abstract] [Full Text] -
Gershon, A. S., de Azavedo, J. C. S., McGeer, A., Ostrowska, K. I., Church, D., Hoban, D. J., Harding, G. K. M., Weiss, K., Abbott, L., Smaill, F., Gourdeau, M., Murray, G., Low, D. E.
(2002). Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000. Antimicrob. Agents Chemother.
46: 1553-1556
[Abstract] [Full Text] -
Shewmaker, P. L., Steigerwalt, A. G., Shealey, L., Weyant, R., Facklam, R. R.
(2001). DNA Relatedness, Phenotypic Characteristics, and Antimicrobial Susceptibilities of Globicatella sanguinis Strains. J. Clin. Microbiol.
39: 4052-4057
[Abstract] [Full Text] -
Bast, D. J., de Azavedo, J. C. S., Tam, T. Y., Kilburn, L., Duncan, C., Mandell, L. A., Davidson, R. J., Low, D. E.
(2001). Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother.
45: 2631-2634
[Abstract] [Full Text] -
Jones, R. N., Pfaller, M. A.
(2000). Potencies of Newer Fluoroquinolones against Viridans Group Streptococci Isolated in 637 Cases of Bloodstream Infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada!. Antimicrob. Agents Chemother.
44: 2922-2923
[Full Text] -
LaClaire, L., Facklam, R.
(2000). Antimicrobial Susceptibilities and Clinical Sources of Facklamia Species. Antimicrob. Agents Chemother.
44: 2130-2132
[Abstract] [Full Text] -
Ferrándiz, M. J., Fenoll, A., Liñares, J., De La Campa, A. G.
(2000). Horizontal Transfer of parC and gyrA in Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother.
44: 840-847
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»